Change in the ration of free-to-total prostate-specific antigen during progression of advanced prostate cancer

International Journal of Urology

Volumn 7, Issue 3, 2000, Pages 83-87

  Tanaka, Masashi ^a,b   Murakami, Shino ^a   Suzuki, Noriyuki ^a   Shimazaki, Jun ^a  

^a CHIBA UNIVERSITY   (Japan)

^b ASAHI GENERAL HOSPITAL   (Japan)

Author keywords

F T ratio; Prostate cancer; Prostate specific antigen; Relapse

Indexed keywords

CHLORMADINONE ACETATE; FLUTAMIDE; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CASTRATION; CONTROLLED STUDY; CORRELATION FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; SERUM; TRANSURETHRAL RESECTION; BLOOD; DISEASE COURSE; METASTASIS; PATHOLOGY; PROSTATE TUMOR;

DISEASE PROGRESSION; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 0033624905     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.2000.00144.x     Document Type: Article

References (27)

1. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkannen K, Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res. 1991; 51: 222-6.
2. van Iersel MP, Witjes WPJ, Thomas CMG, Segers MFG, Oosterhof GON, Debruyne FMG. Review on the simultaneous determination of total prostate-specific antigen and free prostate-specific antigen. Prostate 1996; 7 (Suppl.): 48-57.
3. Alivizatos G, Deliveliotis C, Mitropoulos D et al. Does free to total ratio of prostate-specific antigen alter decision-making on prostatic biopsy? Urology 1996; 48: 71-5.
4. Masters JG, Keegan PE, Hildreth AJ, Greene DRJ. Free/total serum prostate-specific antigen ratio. How helpful is it in detecting prostate cancer? Br. J. Urol. 1998; 81: 419-23.
5. Klingler HC, Woo H, Rosario D et al. The value of prostate specific antigen (PSA) density and free: Total PSA ratio in selecting patients with a normal digital rectal examination and intermediate total PSA levels for further investigation. Br. J. Urol. 1998; 82: 393-7.
6. Morgan TO, McLeod DG, Leifer ES, Murphy GP, Moul JW. Prospective use of free prostate-specific antigen to avoid repeat prostate biopsies in men with elevated total prostate-specific antigen. Urology 1996; 48: 76-80.
7. Reissigl A, Klocker H, Pointner J et al. Usefulness of the ratio free/total prostate-specific antigen in addition to total PSA levels in prostate cancer screening. Urology 1996; 48: 62-6.
8. Recker F, Kwiatkowski MK, Piironen T, Pettersson K, Goepel M, Scholl R. Free-to-total prostate-specific antigen (PSA) ratio improves the specificity for detecting prostate cancer in patients with prostatism and intermediate PSA levels. Br. J. Urol. 1998; 81: 532-8.
9. Kuriyama M, Kawada Y, Arai Y et al. Significance of free to total PSA ratio in men with slightly elevated serum PSA levels: A cooperative study. Jpn. J. Clin. Oncol. 1998; 28: 661-5.
10. Maeda H, Arai Y, Okubo K, Aoki Y, Okada T, Maekawa S. Value of free to total prostate specific antigen ratio and prostate specific antigen density for detecting prostate cancer in Japanese patients. Int. J. Urol. 1998; 5: 343-8.
11. Stenman UH. Prostate-specific antigen, clinical use and staging: Overview. Br. J. Urol. 1997; 79 (Suppl.): 53-60.
12. Arcangeli CG, Shepherd LD, Smith DS, Humphrey PA, Keetch DW, Catalona WJ. Correlation of percent free PSA with pathologic features of Caprostatic carcinoma. J. Urol. 1996; 155: 415A.
13. Arcangeli CG, Humphrey PA, Smith DS et al. Percentage of free serum prostate-specific antigen as a predictor of pathologic features of prostate cancer in a screening population. Urology 1998; 51: 558-65.
14. Partin AW, Oestering JE. The clinical usefulness of percent free-PSA. Urology 1996; 48: 1-4.
15. Partin AW, Catalona WJ, Southwick PC, Subong EP, Gasior GH, Chan DW. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: Influence of total PSA, prostate volume, and age. Urology 1996; 48: 55-61.
16. Hendricks WH, England BG, Giacherio DA, Oesterling JE, Wojno KJ. Free to total PSA ratio does not predict extraprostatic spread of prostatic adenocarcinoma. J. Urol. 1996; 155: 369A.
17. Chandre T, Stackhouse R, Kidd VJ, Robson KJH, Woo SLC. Sequence homology between human α-1-antichymotrypsin, α-1-antitrypsin, and antithrombin III. Biochemistry 1983; 22: 5055-61.
18. Abraham CR, Selkoe DJ, Porter H. Immunochemical identification of the serine protease inhibitor α-1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 1988; 52: 487-502.
19. Stockley RA, Burnett D. Alpha-antichymotrypsin in infected and non-infected sputum. Am. Rev. Respir. Dis. 1980; 122: 81-8.
20. Ravery V, Boccon-Gibod L. Free/total prostate-specific antigen ratio - hope and controversies. Eur. Urol. 1997; 31: 385-8.
21. Björk T, Hulkko S, Bjartell A, di Sant'Agnese A, Abrahamsson PA, Lilja H. Alpha-1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. Urology 1994; 43: 427-34.
22. Tanaka M, Suzuki Y, Takaoka K, Murakami S, Suzuki N, Shimazaki J. Immunohistochemical findings of α-1-antichymotrypsin in tissues of benign prostatic hyperplasia and prostate cancer. Int. J. Urol. 1999; 6: 600-6.
23. Berman G, Burnett D, Woo SLC, Stockley RA. Production of alpha-1-antichymotrypsin by the J 111 cell line. Biolog. Chem. Hoppe-Seyler 1988; 369 (Suppl.): 23-6.
24. Sumi S, Umeda H, Yano M et al. Studies on changes in the ratio of free to total PSA after endocrine treatment of prostate carcinoma. Acta Urol. Jpn 1996; 42: 937-41 (in Japanese).
25. Jennifer DWL, Notboom L, Blumenstein BA, Ellis WJ, Lange PH, Vessella RL. Serum percent free prostate-specific antigen in metastatic prostate cancer. Urology 1998; 52: 366-71.
26. Stein A, Barak M, Mecz Y, Rubinov R, Lurie A. Serum free/total prostatic-specific antigen in prostate cancer patients treated with LH-RH agonists. Eur. Urol. 1997; 32: 64-8.
27. Berruti A, Dogliotti L, Fasolis G et al. Changes in free and free-to-total prostate specific antigen after androgen deprivation or chemotherapy in patients with advanced prostate cancer. J. Urol. 1999; 161: 176-81.